The activity of the autoimmune mechanism underlying type 1 diabetes mellitus (T1DM) can be suppressed when immunoablation and autologous hematopoietic stem cell transplantation (AHSCT) are applied early in the course of the disease. We report here a single centre experience with this treatment modality. Twenty-four patients underwent a AHSCT preceded by immunoablative conditioning with high-dose cyclophosphamide and anti-thymocyte globulin. During the 52-month median time of follow-up 20 out of 23 patients (87%) remained for at least 9.5 months without the use of exogenous insulin. The median time of T1DM remission for these patients was 31 months (range of 9.5-80 months). Among the patients available for follow-up (n = 20), four remain insulin free (for 80, 61, 42 and 34 months). The average glycated hemoglobin (HbA1c) concentrations were 10.9% at diagnosis, 5.9% at 1 year, 6.4% at 2 years, 6.8% at 3 years and 7.1% at 4 years after AHSCT. No severe complications of diabetes were seen, however one of the patients died of pseudomonas sepsis in the course of neutropenia after AHSCT. AHSCT leads to a remission of T1DM with good glycemic control in the vast majority of patients, with the period of remission lasting over 5 years in some patients.
INTRODUCTION
The 'Holy Grail' of type 1 diabetes mellitus (T1DM) treatment is the induction of tolerance towards autoantigens, which serve as targets for an autoimmune reaction underlying this disease. This intervention ideally should also lead to normoglycemia, obviating the need for exogenous insulin injections, and hence lead to an effective 'cure' of this disease. Various approaches have been tried to accomplish this goal: treatment of patients with cytostatic drugs, [1] [2] [3] with monoclonal antibodies, such as rituximab and teplizumab, [4] [5] [6] with vaccines modifying the immune system response 7 or with umbilical cord blood stem cells, 8 to name a few. Most of the studies failed to show any significant and lasting influence on course of T1DM. Immunoablation with autologous hematopoietic stem cell transplantation (AHSCT)-which targets the immune reaction leading to diabetes-is the only treatment that has been shown to achieve, at least temporary, remission of T1DM, given that it is applied early after diagnosis. [9] [10] [11] [12] [13] [14] The effect of this treatment is dependent upon near-complete eradication of the patient's immune system within weeks to months from the initial diagnosis of T1DM-an intervention that slows down the further autoimmune destruction of pancreatic β-cells and allows enough recovery of β-cell function to achieve normoglycemia without the need for exogenous insulin.
Our group has already published the preliminary data of eight patients with new-onset T1DM treated with AHSCT at our centre. 10 We have shown that the patients after AHSCT generally have better glycemic control than the patients treated with standard insulin therapy, and that the AHSCT in T1D treatment could be cost effective. 15 Since then, we have expanded our group of patients to 24 with the average time of observation of around 58 months. In this report, we show the long-term results of patients with new-onset T1DM treated with immunoablation and AHSCT.
MATERIALS AND METHODS
Since 2008, patients diagnosed with T1DM at different hospitals in Poland had consultations with a diabetologist regarding the possibility of treatment with AHSCT. Patients who were interested in this treatment underwent further consultations and assessment at the Department of Internal Diseases, Diabetology and Endocrinology, Central Hospital, Ministry of Interior Affairs and Administration and in the Department of Hematology, Oncology and Internal Medicine of the Medical University of Warsaw. The inclusion criteria included the following: diagnosis of T1D as confirmed by the presence of glutamic acid decarboxylase antibodies (anti-GAD) in 6 weeks prior to inclusion, sustained endogenous secretion of insulin (C-peptide present in the serum), WHO performance status ⩽ 2 and willingness to comply with further general guidelines. The patients with diabetic ketoacidosis were not qualified for the study. The detailed inclusion and exclusion criteria have already been described by our group. 10 The possible risks associated with the procedure were discussed with each patient in detail (including the fertility risks) during the pre-treatment consultation. After the consultation patients' informed consent was acquired. The protocol has been approved by the Bioethics Committee of the Medical University of Warsaw.
The treatment consisted of AHSCT after immunoablative conditioning with high-dose cyclophosphamide with anti-thymocyte globulin (ATG).
and G-CSF, at a dose of 10 μg/kg/day administered from the first day after cyclophosphamide infusion. The mobilization with cyclophosphamide has been chosen to prevent possible flare of autoimmune reaction by G-CSF. After obtaining a sufficient number of CD34+ cells (above 3.0 × 10 6 CD34+ cells/kg of patient body weight) the cells were stored frozen according to the centre protocols. The patients received conditioning with cyclophosphamide in a total dose of 200 mg/kg divided equally on days − 5, − 4, − 3 and − 2, and rabbit ATG (Thymoglobulin Sanofi or ATG Fresenius) given on days − 4, − 3, − 2 and − 1 prior to stem-cell infusion. Three patients in the series were treated with ATG Fresenius (due to a temporary problems with Thymoglobulin availability). Patients received infection prophylaxis according to the centre protocols, as previously described. The dose of the transplanted CD34+ cells was more than or equal to 3.0 × 10 6 cells/kg of patient body weight. The G-CSF was given from day +5 after AHSCT until WBC engraftment.
The follow-up visits were scheduled at 3, 6 and 12 months after AHSCT and later once a year if there was no urgent condition requiring the assistance (of the diabetologist or haematologist). Data has been collected for up to 80 months post AHSCT. Nine patients were not able to fully comply with the follow-up care after 12 months from AHSCT-one moved out of Poland, five could not keep some of the scheduled visits and three were lost to follow-up. The data on insulin use and possible medical complications was gathered yearly via direct contact, via email or over the telephone for 20 out of 23 patients. . After a median 8 days of leukopenia o1500/μL (range 4-13 days) all of the patients underwent a relatively rapid engraftment (WBC count 41000/μL, with a neutrophil count 4500/μL) on day 10 after transplantation (range of 8-13 days).
RESULTS

Twenty
The complications in the course of AHSCT included fever and nausea during the cyclophosphamide/rabbit ATG infusion, that resolved shortly afterwards in most patients. Four patients developed more severe rabbit ATG-related skin reaction/vasculitis (all four after Thymoglobulin), which presented as generalized skin redness (two patients), papular rash on feet and hands (one patient), generalized haemorrhagic rash (one patient). As for infectious complications, 12 out of 24 patients developed neutropenic fever and 4 sepsis-including a fatal case of Pseudomonas aeruginosa sepsis in patient #24. One patient developed pulmonary emphysema after the insertion of a central venous catheter.
At a later time, 30% of patients in follow-up (including five women and two men) developed signs of an autoimmune thyroid disorder (elevated concentrations of anti-thyroglobulin antibodies (TgAb) or/and anti-thyroid peroxidase antibodies)-including one patient with severe Graves' disease. Whereas prior to transplantation, only one patient had a confirmed diagnosis of autoimmune thyroiditis. All of the patients had the thyroidstimulating hormone within normal values prior to AHSCT. Anti-thyroid peroxidase and TgAb were not measured for majority of the patients prior AHSCT, as this is not a standard procedure so far. The time range from transplantation to the onset of the thyroid disease was 5.5 to 15 months. Up until the submission of this manuscript, out of the patients who developed signs of an autoimmune thyroid disorder only two patients required treatment-one patient with Graves' disease (patient #6), and one patient with autoimmune thyroiditis. The Graves' disease in patient #6 had been diagnosed before the transplantation. In this patient the levels of anti-thyroid peroxidase antibodies and TgAb were lower 6 months after the transplantation than compared with before transplantation (time of transplantation-anti-thyroid peroxidase antibodies 12.2 IU/ml and TgAb 540 IU/ml and thyroidstimulating hormone 2.25 μIU/L; 6 month follow-up visit-antithyroid peroxidase antibodies 9.1 IU/ml; TgAb 20.3 IU/ml and thyroid-stimulating hormone 3.29 μIU/ml). However, the patient developed a severe form of Graves' disease with orbitopathy and required steroid treatment 1 year later. Once steroid treatment was initiated, the insulin independence was lost and finally the patient required doses of insulin up to 40 IU/day. Eventually the patient #6 underwent strumectomy 36 months post HSCT. After this surgical intervention, the insulin dose could be reduced, until 3 months post operation insulin was discontinued. However, the patient once again returned to insulin treatment after 4 months of T1D remission.
Insulin use
The average pre-treatment dosage of insulin was 0.34 IU/kg, which declined to 0.23 IU/kg after mobilization with cyclophosphamide and further down to 0.01 IU/kg 1 month after the AHSCT. Twenty out of 23 patients (87%) went into remission of diabetes, defined as independence of exogenous insulin with normoglycemia for at least 9.5 months. The median time of remission for these patients was 31 months (range of 9.5 − 80 months), and 33 months (range of 9.5-80 months) if the patients lost to follow-up are excluded. The insulin dose remained significantly lower during the first 3 years after AHSCT and was 0.04 IU/kg at 1 year (P = 0.0000002), 0.12 IU/kg at 2 years (P = 0.0003) and 0.18 IU/kg at 3 years after AHSCT (P = 0.02). In following 2 years, the insulin doses returned to pre-AHSCT values at 0.22 and 0.35 IU/kg, 4 and 5 years after AHSCT, respectively. Among the patients remaining in follow-up (n = 20), four remain insulin free with follow-up periods of 80, 61, 42 and 34 months. All patients after AHSCT have shown a good glycemic control with the average glycated hemoglobin (HbA1c) concentrations of 10.9% at the time of diagnosis that improved to 5.9% at 1 year after AHSCT. The values went up in following years to 6.4% at 2 years, 6.8% at 3 years and 7.1% at 4 years after AHSCT.
Notably, there were three patients in the series who were treated with ATG Fresenius at a total dose 23, 23 and 31 mg/kgthe follow-up of these patients is 58, 59 and 80 months, with the period of being insulin free of 52, 44 and 80 months, respectively. If these three patients are subtracted from the full group of patients, the median length of time without the need for insulin of the remaining patients is 23 months (range of 0-61 months, n = 20)-this is including the three patients lost to follow-up and the three not responding to treatment. Although the average time of T1DM remission in the subgroup of patients treated with ATG Fresenius is more than doubled compared with that of patients treated with Thymoglobulin (22 months), the small number of patients in the former subgroup makes the statistical analysis unreliable (average remission time of 58 vs 22 months, P = 0.06).
The duration of diabetes remission did not correlate with the time from diagnosis to treatment (shorter than 2 months (n = 11) vs longer than 2 months (n = 12); remission duration of 28 vs 27 months, P = 0.99), nor the dose of the stem cells (below 4.5 × 10 6 CD34/kg (n = 13) vs higher dose (n = 10); remission duration of 29 vs 25 months, P = 0.73). Also, initial insulin use, initial fasting and postprandial C-peptide concentrations did not correlate with the duration of remission. Neither the time between diagnosis and transplantation, nor the stem cell dose at transplantation, correlated with the required insulin dose at 12, 24, 36 months post AHSCT.
DISCUSSION
Key results
AHSCT can induce remissions of new-onset T1DM in most of the patients treated. We found that 87% of the patients with newonset T1DM remained insulin free for a median time of 31 months following immunoablation and transplantation. Four patients remained in remission at their last follow-up visit, while the rest returned to their insulin dose from prior to transplantation on average 5 years from treatment. Despite the fact that the majority of patients returned to insulin treatment, AHSCT can still be cost effective if the patients with T1DM undergoing this therapy maintain better glycemic control than patients treated with insulin. 15 This can be reached if the effect of AHSCT, measured as HbA1C concentration, is sustained for over 3-8 years. Moreover, the preservation of pancreatic β-cell function is one of the factors protecting the patients against long-term complications-which is evident in our group of patients, as all who underwent treatment have sustained an adequate postprandial C-peptide response, aside from the remission of T1DM. It is still unclear how the efficacy of the treatment could be improved. An increased number of transplanted hematopoietic stem cells was reported in patients with longer periods of T1DM remission after AHSCT 14 -we were unable to confirm this finding in our group and the observation of a bigger group of patients by D'Addio might be biased by the patients from our group with relatively good outcomes. The time to transplantation seems to be an important factor-the shorter it is, the better the outcome of the T1DM patients. 14 In our group, all of the patients were transplanted within 4 months from diagnosis-and the patients transplanted under 2 months did not differ significantly with respect to their remission time from those transplanted between 2-4 months after diagnosis (remission time of 28 months versus 27 months).
The type of conditioning regimen might also have a role in the efficacy of the AHSCT. The cyclophosphamide effectiveness in pre-AHSCT conditioning might depend on the metabolism of the drug by the given patient and is not subject to standard monitoring. 16 Moreover, there is no data comparing thymoglobulin, which is a standard ATG substance used in most of the transplantation centres, to other ATG substances when it comes to patients with autoimmune disease. Three of our patients received ATG Fresenius-which seemed to have less side effects at the doses used than thymoglobulin; in addition, it produced remissions of more than double the duration when compared with other patients. This finding has to be interpreted with caution, as there is no randomised data in autoimmune diseases recommending any formulation of rabbit ATG over another. It would be quite interesting to see if there are any variations in the outcomes of patients treated with high-dose cyclophosphamide and different formulations of ATG in other autoimmune diseases.
Furthermore, recently published data has shown that use of different AHSCT regimens with co-transplantation of insulinsecreting cells might give enduring responses in T1DM. 17 Cyclophosphamide and ATG fail to induce the permanent immunosuppression when given pre-AHSCT; however, the authors used combination of bortezomib, methylprednisone and rabbit ATG given post AHSCT-likely aiming at clonal elimination of reactive lymphocytes. This strategy will be less toxic but we still need to see long-term effectiveness of such treatment. Also the safety of the Cy ATG conditioning regimen is still questionable, as its mortality is higher than the natural mortality due to diabetes. 18 Could such mortality be accepted by patients and physician? To answer this question we conducted a pool among participants at major diabetes conference in Poland after the presentation of results of this study (data not published). None of the physicians accepted the treatment-related mortality over 1% for this treatment and 14.6% said that 0% treatment-related mortality would only be acceptable. However, after the presentation of the current data 12% of pooled physicians would send patients with new-onset T1D for AHSCT and 60% would consider it if it was a patient's wish. Eighteen per cent said that they would not send patients for this treatment. If they were to recommend AHSCT to the patients for any indication there were more likely to do it with multiple sclerosis (64%), systemic sclerosis (14%) than with T1D (10%) or Crohns' disease (10%). These data show that despite the observed mortality and limited effect, the treatment can be accepted by many physicians. It would be extremely interesting to know the AHSCT T1D patient views on the treatment they underwent-would they reconsider doing it again if they could make this choice one more time? Again the changes in conditioning and switch from pre transplantation immunoablation to post transplantation clonal elimination of reactive lymphocytes are likely to reduce or even eliminate mortality of this treatment. Ideally AHSCT must reach a level of safety comparable to the natural mortality due to diabetes complications-which is 0.1% in first 10 years after diagnosis.
Limitations
The presented results show the effectiveness of AHSCT in a series of patients with new-onset T1DM. The study is one centre only and is non-randomised-so the results could be biased. We cannot asses the number of disease remissions that can be attributed to the 'honeymoon' phase of diabetes-the remissions of T1DM may happen spontaneously in a small proportion of patients. A randomised multicentre clinical trial could resolve this question.
We were unable to fully maintain the planned schedule for follow-up visits-especially of patients #20 and #21, who remained in remission until their last follow-up-roughly 1 year after HSCT. Another factor influencing our results was the behaviour of the patients after AHSCT. The diabetic diet and a healthy life style was recommended for all patients-however, some of the patients seemed rather reluctant to follow it. It is easier for many patients to take 2-4 IU of insulin before bigger meals and not be restricted by what they eat. Due to the socioeconomic changes after Poland joined the European Union (EU), some of our patients started to work abroad and were reluctant to travel back to our centre for follow-up visits.
If the patient's glycemic control was not sufficient during the follow-up visits, insulin was once again given to the patient. The HbA1C concentration tended to be higher during the routine follow-up visit when insulin was introduced than during the unscheduled visits after the patients were returned to insulin use. This way the average concentration of HbA1C for the patients could be higher on follow-up visits than the HbA1C between visits.
CONCLUSIONS
Despite its limitations, the study provides further proof that AHSCT can induce remissions in new-onset T1DM. The AHSCT is not a 'magic bullet'-it has substantial risk for the patients and it fails to cure diabetes. However, it proves that when the immune reaction against a β-cell is halted, the diabetes can go into remission, temporary for most of the patients. Despite the return to insulin use after some time post AHSCT the patients can still benefit long term with improvement in glycemic control. What AHSCT in T1D needs are strategies to improve safety and push the mortality level of this procedure below a rate of 0.1%, and to achieve at least a 3-to 8-year advantage of AHSCT over standard insulin therapy, as measured by lower HbA1C concentration. If these goals are achieved this treatment may become an alternative to standard insulin therapy for some patients with new-onset T1DM.
